Billings Clinic
Especially For:

Clinical Trials

Title   Melanoma: E1609 First line
Description   Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4
Therapy Versus High-Dose Interferon a-2b for Resected High-risk
Melanoma
IRB Number   CTSU E1609
Category   Melanoma
Inclusion/Notes   Open to completely resected melanoma.
Pts must be randomized w/in 84 days of surgical resection
No previous chemotherapy allowed
Previous irradiation is allowed as long as 30 days have elapsed prior to study start
Status   Active
Start Date   08/12/2011
Principal Investigator (PI)   Jorge Nieva, MD
Contact Name   Judy Miller, RN
Contact Email   jmiller4@billingsclinic.org
Phone   (406) 435-7482
Alternate Phone   (406) 435-7480
Fax   (406) 435-7489
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.